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CD44 enhances invasion of basal-like breast
cancer cells by upregulating serine protease and
collagen-degrading enzymatic expression and
activity
Nicola Montgomery1†, Ashleigh Hill1†, Suzanne McFarlane1, Jessica Neisen1, Anthony O’Grady2, Susie Conlon2,
Karin Jirstrom3, Elaine W Kay2 and David JJ Waugh1*
Abstract
Introduction: Basal-like breast cancers (BL-BCa) have the worst prognosis of all subgroups of this disease.
Hyaluronan (HA) and the HA receptor CD44 have a long-standing association with cell invasion and metastasis of
breast cancer. The purpose of this study was to establish the relation of CD44 to BL-BCa and to characterize how
HA/CD44 signaling promotes a protease-dependent invasion of breast cancer (BrCa) cells.
Methods: CD44 expression was determined with immunohistochemistry (IHC) analysis of a breast cancer tissue
microarray (TMA). In vitro experiments were performed on a panel of invasive BL-BCa cell lines, by using
quantitative polymerase chain reaction (PCR), immunoblotting, protease activity assays, and invasion assays to
characterize the basis of HA-induced, CD44-mediated invasion.
Results: Expression of the hyaluronan (HA) receptor CD44 associated with the basal-like subgroup in a cohort of
141 breast tumor specimens (P = 0.018). Highly invasive cells of the representative BL-BCa cell line, MDA-MB-231
(MDA-MB-231Hi) exhibited increased invasion through a basement membrane matrix (Matrigel) and collagen. In
further experiments, HA-induced promotion of CD44 signaling potentiated expression of urokinase plasminogen
activator (uPA) and its receptor uPAR, and underpinned an increased cell-associated activity of this serine protease
in MDA-MB-231Hi and a further BL-BCa cell line, Hs578T cells. Knockdown of CD44 attenuated both basal and HA-
stimulated uPA and uPAR gene expression and uPA activity. Inhibition of uPA activity by using (a) a gene-targeted
RNAi or (b) a small-molecule inhibitor of uPA attenuated HA-induced invasion of MDA-MB-231Hi cells through
Matrigel. HA/CD44 signaling also was shown to increase invasion of MDA-MB-231 cells through collagen and to
potentiate the collagen-degrading activity of MDA-MB-231Hi cells. CD44 signaling was subsequently shown to
upregulate expression of two potent collagen-degrading enzymes, the cysteine protease cathepsin K and the
matrix metalloprotease MT1-MMP. RNAi- or shRNA-mediated depletion of CD44 in MDA-MB-231Hi cells decreased
basal and HA-induced cathepsin K and MT1-MMP expression, reduced the collagen-degrading activity of the cell,
and attenuated cell invasion through collagen. Pharmacologic inhibition of cathepsin K or RNAi-mediated
depletion of MT1-MMP also attenuated MDA-MB-231Hi cell invasion through collagen.
Conclusion: HA-induced CD44 signaling increases a diverse spectrum of protease activity to facilitate the invasion
associated with BL-BCa cells, providing new insights into the molecular basis of CD44-promoted invasion.
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Introduction
Breast cancer is a heterogeneous disease, currently
defined as a minimum of five distinct molecular subtypes
[1]. Of these subtypes, “basal-like” breast cancer (BL-
BCa) has the worst clinical outcome and is associated
with an increased risk of hematogenous metastasis, pre-
dominantly to the lungs and liver [2]. An enhanced
understanding of the mechanisms and factors that under-
pin the local invasion and the capacity of BL-BCa cells to
escape from the primary tumor, or invade secondary
tumor sites, would have significant impact on improving
the outcomes for this disease subtype.
Hyaluronan (HA) is a constituent of extracellular
matrix, which can induce marked effects on cell behavior
by binding to its predominant cell-surface receptor CD44
[3]. Before the era and definition of the molecular sub-
types, elevated levels of HA in tumor stroma were shown
to correlate with poorly differentiated tumors, auxiliary
lymph node status, and short overall survival in breast
cancer [4,5]. Klingbeil and colleagues [6] recently deter-
mined that CD44 expression associates with the BL-BCa
subtype. Furthermore, we recently determined that CD44
is inversely associated with estrogen receptor (ER)
expression, with strong expression localized to basal cells
[McFarlane S, Conlon S, O’Grady A, Kay EW, Waugh
DJJ, unpublished observations]. Consistent with an asso-
ciation with the most clinically aggressive tumors, in
vitro studies have demonstrated the role of HA and
CD44 in stimulating breast cancer cell migration and cell
invasion. We have shown that tetracycline-induced
expression of CD44 in the noninvasive, luminal MCF-7
breast cancer cell line is alone sufficient to induce cell
invasion in response to HA in vitro [7]. The induction of
CD44 also was sufficient to promote the spontaneous
metastasis of these noninvasive luminal breast cancer
cells to the liver in vivo [8]. Clinical studies have also
confirmed the enrichment of CD44 expression in disse-
minated tumor cells resident in secondary tissue sites
[9,10].
Metastasis demands that cancer cells invade through
the physical barriers provided by the extracellular matrix
of the primary and secondary tumor sites and the base-
ment membranes present within each of these tissue
sites. Activation of proteolytic enzymes is thought to be
essential in facilitating the degradation of the proteins
that constitute these physical structures. Interestingly,
two enzymes of the matrix metalloproteinase (MMP)
family, MMP-9 and MMP-7, were previously shown to
complex with the ectodomain of CD44 on the surface of
malignant cells, suggesting that CD44 acts in a structural
capacity to concentrate protease activity on the surface of
actively invading cells [11,12]. Moreover, CD44 itself is a
substrate of a further MMP, which complexes with the
membrane-tethered enzyme MT1-MMP and is then
cleaved by the enzyme [13,14]. Although these studies
suggest that CD44 cooperates with MMPs to regulate
cell invasion, the relation of HA-induced CD44 signaling
to the regulation of protease expression and activity in
invasive breast cancer cells is poorly defined. Moreover,
it is well known that malignant breast cancer cells
express other protease species in addition to those of
MMPs, including the serine protease urokinase plasmi-
nogen activator (uPA), a marker of poor prognosis and
associated with BL-BCa [15,16].
The objective of our study was to increase our under-
standing of CD44-promoted breast cancer cell invasion
by defining the effect of CD44 signaling on protease
gene expression and activity, and defining the role of
these proteases in underpinning HA-induced invasion.
Informed by studies on breast cancer tissue reaffirming
the association of CD44 with the basal-like subtype of
breast cancer, we show that CD44 signaling amplifies
serine protease, MMP, and/or cysteine cathepsin gene
expression and activity, all of which contribute to the
invasion of BL-BCa cells through a specialized matrix.
Our studies thus provide a new molecular insight to
substantiate the association of CD44 with the metastasis
of breast cancer.
Materials and methods
Tissue microarray construction and
immunohistochemistry
Breast tumor samples were collected and data recorded as
described previously [17]. Then 4 μm sections were cut
from the TMA and immunostained with anti-CD44 on an
automated platform (Bond system; Vision BioSystems,
Mount Waverley, Victoria, Australia). In brief, cut sections
were subjected to on-board dewaxing (Dewax solution;
Vision BioSystems) and antigen retrieval (Epitope Retrieval
1 solution; Vision BioSystems) for 20 minutes before
application of primary antibody (1:200) and detection by
using the Bond polymer Refine detection system (Vision
BioSystems). All sections were counterstained with hema-
toxylin. Negative controls were included for all sections by
the omission of primary antibody. Positive control tissue
(normal thymus) was also used. Immunostained slides
were scored on the proportion of positive tumor cells
(range, 0 to 4) and the average intensity of staining (range,
0 to 3). These values were added to obtain a total score
(range, 0 to 7). All scores were examined by two indepen-
dent observers (SMcF and SC), and 10% were also scored
by a third independent observer (EK). An expression cor-
relation analysis between CD44 and the basal-like subtype
in breast cancer cells and primary tumors was also per-
formed by using Oncomine (Compendia Bioscience, Ann
Arbor, MI, USA).
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Cells
The MDA-MB-157 cell line was purchased from Amer-
ican Type Culture Collection (ATCC) (Manassas, VA,
USA) and cultured as previously described [7]. Hs578T
cells were provided by Dr Paul Mullan (CCRCB,
Queen’s University Belfast) and cultured as described
[18]. The highly invasive clone, MDA-MB-231Hi, was
provided, complete with matched parental cells by
Prof. Toshiyuki Yoneda (University of Health Sciences,
San Antonio, TX, USA) and were cultured in DMEM
supplemented with 10% vol/vol fetal calf serum (FCS)
(Invitrogen Life Technologies, Paisley, UK) [19]. CD44-
depleted MDA-MB-231 cells (termed MDA-MB-231
sh#1) were generated in our laboratory by stable trans-
fection with a CD44 shRNA; parallel transfection with
a nontargeting shRNA was used as a control to gener-
ate MDA-MB-231 NT cells (McFarlane S, et al.,
unpublished data) and cultured in DMEM supplemen-
ted with 10% vol/vol FCS, 0.2 μg/ml puromycin. All
cell lines were grown to 70% confluence before
experimentation.
Reagents and antibodies
Chemicals were supplied by Sigma Chemical Co. (St.
Louis, MO, USA) unless otherwise stated. Hyaluronan of
molecular mass 220 kDa and medical-grade purity was
purchased from Lifecore Biomedical Inc. (Chaska, MN,
USA). The cathepsin K inhibitor was purchased from
Calbiochem (La Jolla, CA, USA). Pefabloc uPA inhibitor
was supplied by DSM Nutritional Products Ltd Branch,
Pentapharm (Basel, Switzerland). Specific RNAi SMART-
pools for CD44, uPA, and MT1-MMP, the nontargeting
siCONTROL RNAi oligonucleotide, and Dharmafect 2
transfection reagent were obtained from Dharmacon
(Lafayette, CA, USA). The mouse anti-human CD44
monoclonal antibody (1:500), mouse anti-human uPAR
mAb (1:500 dilution), and mouse anti-human serpin E1/
PAI-1 mAb (1:500) were obtained from R&D Systems
(Abingdon, UK). Abcam (Cambridge, UK) supplied the
rabbit anti-cathepsin K pAb (1:100). The mouse anti-
human urokinase mAb (1:500) and the mouse anti-
human PAI-2 mAb (1:3,000) were provided by American
Diagnostica (Stamford CT, USA). The mouse anti-
MMP14 (MT1-MMP) mAb (1:1,000) was obtained from
Chemicon (Watford, UK). Mouse anti-human GAPDH
mAb (1:3,000) was supplied by AbD Serotec (Oxford,
UK). Sigma (UK) supplied the mouse anti-human b-
tubulin mAb (1:1,000). The sheep anti-mouse IgG/horse-
radish peroxidase conjugate (1:2,000) and donkey anti-
rabbit IgG/horseradish peroxidase conjugate (1:2,000)
secondary antibodies were purchased from Amersham
(Amersham, UK). The anti-p38 MAPK antibody (1:1,000)
was supplied by Cell Signaling Technologies (Beverly,
MA, USA).
Quantitative PCR analysis
RNA was harvested and cDNA was synthesized from 10 to
20 μg total RNA, as previously described [7]. Analysis was
performed on a Roche LC480 Light Cycler (Roche Diag-
nostics GmbH, Mannheim, Germany), with product
amplification determined by SYBR Green 1 fluorescence
detection. Forward (Fwd) and reverse (Rev) primers are as
shown: CD44 Fwd TTTGCATTGCAGTCAACAGTC;
CD44 Rev GTTACACCCCAATCTTCATGTCCAC;
Cathepsin K Fwd AGGCTTCTCTTGGTGTCCATA;
Cathepsin K Rev CCTTTCTTTCGATAGTCGACA;
MT1-MMP Fwd AATATGGCTACCTGCCTCCC; MT1-
MMP Rev TTGCCATTTGAGACCCTGGAT; uPA Fwd
GAGGCCCCGCTTTAAGATTA; uPA Rev TGGAGT-
TAAGCCTTGAGCGA; uPAR Fwd AAGATCAC-
CAGCCTTACCGA; uPAR Rev CCTTCTTCACCTTCC
TGGAT; PAI-1 Fwd CTGACAACAGGAGGAGAAAC;
PAI-1 Rev GGAACAGCCTGAAGAAGTGG; PAI-2 Fwd
ACCCAGAACCTCTTCCTCTC; PAI-2 Rev TGGTAAA
GTTCTCTGGAGTCA; 18S Fwd CATTCGTATTGC
GCCGCTA; 18S Reverse CGACGGTATCTGATCGTC.
Reactions were conducted by using 1 μl of cDNA reverse
transcribed from 10 to 20 μg total RNA, 0.4 μM final con-
centration of forward and reverse primers and 2 × SYBR
Green 1 master mix (Roche Diagnostics). Standard cycling
procedures were used, with annealing temperatures of
51°C used for the CD44 and 18S, 54°C for uPAR, 55°C for
cathepsin K, 55.7°C for MT1-MMP, and 57°C for the uPA,
PAI-1, and PAI-2 primer pairs. Specific amplicon forma-
tion with each primer pair was confirmed by melt-curve
analysis. Gene expression was quantified relative to an 18S
housekeeping gene.
Knockdown of CD44, uPA, and MT1-MMP expression in
cancer cells
Cells were seeded to approximately 70% confluence before
transfection with the relevant RNAi SMARTPool or the
nontargeting RNAi oligonucleotide by using Dharma-
FECT-2 according to the manufacturer’s instructions.
Immunoblotting
Protein samples were collected, quantified, and blotted
as previously described [20] by using the antibodies
described. Immunoreactivity was detected by using che-
miluminescence (Supersignal; Pierce). Equal loading of
the protein samples was assessed by reprobing the
membrane with either a GAPDH or b-tubulin antibody.
uPAR flow cytometry
Samples were analyzed for cell-surface uPAR expression
as previously described [21] by using a fluorescein-conju-
gated murine anti-human monoclonal uPAR antibody
(American Diagnostica Inc., Stamford, CT, USA) and an
IgG control antibody (R&D Systems, Abingdon, UK).
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Invasion assays
Invasion chambers were prepared by coating cell-culture
inserts (12-μm pore size; Costar) with either 2 μg/cm2
of Collagen I (BD Biosciences, Erembodegem, Belgium)
or 100 μg/cm2 of Matrigel (BD Biosciences) alone or
supplemented with HA at a final concentration of 100
μg/cm2 in phenol red-free DMEM. Assays were con-
ducted as previously described [7]. In some experiments,
the invasive capacity of the cells was determined by
using the xCELLigence cell analyzer system (Roche
Diagnostics). The top chambers of CIM invasion plates
were coated with Matrigel (5%) and allowed to dry for 4
hours at 37°C. Prewarmed phenol red-free DMEM sup-
plemented with FCS was added to the lower chambers
before the upper chamber was locked into place and 30-
μl serum-free medium added to each well. The invasion
apparatus was allowed to equilibrate at 37°C for 1 hour,
after which 1 × 105 cells in serum-free medium were
seeded into the top wells and allowed to settle for 30
minutes. The plates were then loaded onto the xCELLi-
gence analyzer, and electrical impedance was measured
every 15 minutes over a 36-hour period.
uPA activity assays
uPA activity was determined by using a uPA Activity
Assay Kit (Chemicon International) according to the
manufacturer’s instructions on either cell lysate or cell
media samples. In brief, a standard curve was generated
by the addition of varying amounts of the uPA-positive
control (10 to 160 μl) in duplicate to a clear 96-well
plate. Then 50μl cell lysate samples or 10 μl of cell
media samples was added to the 96-well plate along
with a either a media or RIPA buffer blank. Sufficient
deionized water was added to bring the total volume of
each well to 160 μl. Then 20 μl assay buffer was added
to each well, followed by 20 μl of chromogenic sub-
strate. The plate was incubated in the dark at 37°C for
periods between 10 minutes and 8 hours, depending on
uPA levels contained in samples. The optical density of
each well was determined by using a standard micro-
plate reader (405 nm). Duplicate OD readings for each
sample were averaged, and the relevant blanks were sub-
tracted. Samples were compared with the standard curve
to obtain relative uPA activity. Results are expressed as
fold change over control cells.
Plasmin activity assays
Cells were plated at a density of 2 × 104 cells per well in
200 μl of phenol red-free medium and allowed to reach
approximately 70% confluence. Cell-free medium (200
μl) was added to a well as a negative control, and 3 μg
human plasminogen (Hyphen BioMed, ZAC Neuville
University, France) was added to each well and incu-
bated at 37°C for 30 minutes, and 65 μl of assay buffer
(100 mM Tris/0.5% TritonX-100, pH 8.8) and 15 μl S-
2251 substrate (25 μg) (Chromogenix, Milan, Italy) was
added to the wells of a separate 96-well plate. After a
30-minute incubation period, 20 μl of each sample was
added in duplicate to wells. Human plasmin was imple-
mented to generate a standard curve, from which plas-
minogen activation rates of unknown samples were
determined. Plasmin of varying amounts was added to
the wells of the 96-well plate containing assay buffer
and S-2251 substrate. The plate was covered, and the
optical density for each well at 405 nm was determined
by using a standard microplate reader at regular inter-
vals. Plasminogen is activated to form plasmin that is
able to cleave the chromogenic substrate S-2251. The
method for determination of activity is based on the dif-
ference in absorbance at 405 nm. Duplicate OD readings
for each sample were averaged, and the mean media
blank subtracted. Samples were compared with the plas-
min standard curve to obtain relative plasmin units of
activity. Results were then quantified relative to cell
number for each sample, and expressed as relative plas-
min units of activity per 1 × 106 cells.
Cathepsin K ELISA
Breast cancer cells were seeded at a density of 1 × 105
cells/500 μl in a 24-well plate and allowed to reach 70%
confluence before experimentation. Cell-culture super-
natants were collected and cell debris removed by cen-
trifugation. Cell counts were taken from each
experimental well to allow normalization of cathepsin K
concentration to cell number (106 cells). The cathepsin
K ELISA (Biomedica Gruppe, Vienna, Austria) was con-
ducted as per the manufacturer’s instructions. In brief,
50 μl of the sample, standards or cathepsin K control
were added to the polyclonal sheep anti-cathepsin K-
coated microtiterstrips and incubated at room tempera-
ture for 20 to 24 hours in the dark. The samples, stan-
dards, and control were aspirated and wells washed 5
times with wash buffer. The 200-μl substrate was added
to each well and incubated for 30 minutes at room tem-
perature in the dark. The 50-μl STOP solution was
added to each well, and the absorbance was immediately
read. The sample concentration was calculated from the
standard curve, and the concentration normalized to 106
cells by using previously determined cell counts.
EnzChek collagen degradation assay
Collagenase activity was measured by using the EnzChek
Gelatinase/Collagenase assay kit (Molecular Probes,
Eugene, OR, USA) according to the manufacturer’s
instruction. In brief, cells were grown in P90s in serum-
containing media and allowed to reach 80% confluence
before concentration of the cell culture media by using
Centriplus centrifugal filter units (Millipore, Billerica,
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MA, USA). The concentrated protein samples were
quantified by using the BCA assay, and 1 mg protein
was loaded in duplicate onto a 96-well black fluores-
cence plate. Then 20 μl of DQ Collagen type I fluores-
cein conjugate (Molecular Probes) was loaded into each
well along with 80 μl 1 × Running Buffer. The collage-
nase Clostridium (0.025 U/ml) was run as a positive
control and running buffer acted as a negative control.
As an additional control, cell-culture media (in the
absence of cells) was assessed to ensure that the collage-
nase activity was solely restricted to enzymes secreted
by the breast cancer cells. The fluorescence intensity
was read at 37°C in a fluorescence microplate reader
(Cytofluor 4000; Applied Biosystems, Warrington, UK)
over a 6- to 8-hour period with fluorescent readings
taken every 30 minutes. Collagenase activity over the
time period was reported as fluorescence on subtraction
of the cell-culture media fluorescence.
Statistical analysis of experimental data
Differences between data points (invasion and enzyme
activity assays, ELISA experiments) were assessed for
statistical significance by using the two-tailed Student t
test comparisons (GraphPad Prism 5 software).
Results
CD44 expression correlates with triple-negative, basal-like
breast cancers
CD44 expression was assessed in a breast cancer tissue
microarray composed of tissue cores extracted from a
total of 141 patients, representing all molecular subtypes
of the disease. ER was expressed by 86.7% (121 of 140)
of the cases, and PR was expressed in 69% (96 of 140)
of cases. Expression of CD44 was detected in 60% (84 of
141) of the cases, with strong expression detected in
46% (65 of 141) of the cases analyzed. A strong inverse
correlation between CD44 expression and ER status (P
= 0.025) and PR status (P = 0.021) was found, but no
correlation was found to Her2 expression. Instead,
CD44 expression was strongly correlated with the basal-
like phenotype (P = 0.018) and the triple-negative sub-
type (P = 0.018) (Table 1).
To validate these results further, we performed an
Oncomine analysis of two publically available breast
cancer datasets [18,22]. Expression of CD44 was
strongly associated with basal-like tumors (Figure 1A).
Moreover, the expression of CD44 was preferentially
distributed to basal-like cell lines, as opposed to luminal
cell lines (Figure 1B).
Characterization of increased CD44 expression and
importance to invasion in basal-like breast cancer cells
Given the strong correlation of CD44 expression to the
basal-like subgroup of breast cancers, a series of in vitro
experiments was performed by using cell lines represen-
tative of this subtype, primarily by using the invasive
MDA-MB-231 cell line and a highly metastatic deriva-
tive MDA-MB-231 cell line (MDA-MB-231Hi). After
qPCR and immunoblotting analysis, we confirmed that
MDA-MB-231Hi cells were heavily enriched for CD44
at both mRNA (Figure 1C) and protein level (Figure
1D) when compared with their parental MDA-MB-231
counterparts, and were more invasive through Matrigel
(Figure 1E). The importance of CD44 and its elevated
expression in underpinning the more-efficient invasion
of MDA-MB-231Hi cells was confirmed by using an
Table 1 Association of CD44 with molecular characteristics of breast tumors
Association of CD44 expression with tumor characteristics
n (%) CD44 n (%) P
CD44 + 84/141 (60%) N/A
- 57/141 (40%) N/A
ER + 121/140 (86%) 73/121 (60%) 0.025 Mann-Whitney,
0.019 t test
- 19/140 (14%) 16/19 (84%)
PR + 96/140 (69%) 56/96 (58%) 0.021 Mann-Whitney,
0.025 t test
- 44/140 (31%) 33/44 (75%)
Her2 + 13/133 (10%) 75/120 (63%) Not significant
- 120/133 (90%) 8/13 (62%)
Basal + 15/135 (11%) 13/15 (87%) 0.018 Mann-Whitney,
0.021 t test
- 120/135 (89%) 72/120 (60%)
Triple negative + 15/135 (11%) 13/15 (87%) 0.018 Mann-Whitney,
0.021 t test
- 120/135 (89%) 72/120 (60%)
Expression of CD44 is expressed as a percentage of patients in individual clinical classifications (first column).
Montgomery et al. Breast Cancer Research 2012, 14:R84
http://breast-cancer-research.com/content/14/3/R84
Page 5 of 19
MD
A-
MB
-23
1
MD
A-
MB
-23
1H
i
0
1
2
3
4
5
**
R
el
at
iv
e 
C
D
44
m
R
N
A 
ex
pr
es
si
on
MD
A-
MB
-23
1
MD
A-
MB
-23
1H
i
0
5
10
15
20
25
30
35 *
%
 C
el
l I
nv
as
io
n
NT
 R
NA
i
CD
44
 R
NA
i
0.00
0.25
0.50
0.75
1.00
**
C
el
l I
nv
as
io
n 
In
de
x
(A) (B) 
(D) 
(E) 
(C) 
CD44 
β-tubulin 
(F) 
Basal A & 
Basal B  
Luminal  Basal-like  Luminal  
Figure 1 Association of CD44 with highly aggressive breast tumor subtypes or highly invasive breast cancer cells. Oncomine analysis of
CD44 expression in breast cancer demonstrated significantly higher CD44 mRNA expression in (A) basal-like breast cancer tumors in comparison
with luminal tumors and in (B) basal-like breast cancer cells lines in comparison with luminal-like cell lines (P = 1.90E-6). (C) Bar graph showing
elevated CD44 mRNA transcript levels present in the MDA-MB-231Hi cells compared with the MDA-MB-231 parental cells (3.26-fold increase; n =
5; P < 0.01). (D) Representative immunoblot showing upregulation of CD44s in MDA-MB-231Hi cells relative to the MDA-MB-231 parental cell
line. The blots were reprobed with b-tubulin as a loading control. (E) Bar graph illustrating the elevated invasive capacity of the MDA-MB-231Hi
cells (32.28% ± 2.33% of invaded cells/total number of cells; n = 3; P < 0.05) through Matrigel relative to the MDA-MB-231 cells (18.23% ±
2.071%). (F) CD44 knockdown in MDA-MB-231Hi reduced the cell-invasion index over a 36-hour period through Matrigel from 0.89 ± 0.07 to 0.24
± 0.11 (n = 3; P < 0.01). Statistically significant differences were determined by using a Student two-tailed t test (*P < 0.05; **P < 0.01).
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RNAi strategy targeting this cell-surface receptor;
knockdown of CD44 (validated in Additional file 1, Fig-
ure S1A) significantly reduced invasion of the MDA-
MB-231Hi cells through Matrigel (Figure 1F).
Characterization of elevated uPA activity in highly
invasive basal-like breast cancer cells
uPA is a serine protease associated with the invasion and
intravasation of cancer cells [23-25]. The expressions of
uPA, its receptor uPAR, and its endogenous inhibitors
PAI-1 and PAI-2 were characterized at mRNA and protein
levels. Transcript levels for uPAR and PAI-1 were elevated
in the more-invasive MDA-MB-231Hi cells, whereas PAI-
2 expression was decreased relative to MDA-MB-231 par-
ental cells. No change was noted in uPA mRNA levels
(Figure 2A). Immunoblotting experiments, however, con-
firmed an increase in uPA, uPAR, and PAI-1 expression in
the more-invasive MDA-MB-231Hi cells, whereas PAI-2
expression was again decreased relative to MDA-MB-231
cells (Figure 2B). Flow-cytometry analysis confirmed an
increased level of cell-surface expression of uPAR in the
MDA-MB-231Hi cells relative to MDA-MB-231 cells (Fig-
ure 2C). Activity assays were used to detect changes in
uPA activity, measured within a “cell-associated” fraction
and within the supernatant of the cell culture. Activity of
this serine protease was significantly higher in both the
cell-associated fraction (Figure 2D) and the supernatant
(Figure 2E) of the MDA-MB-231Hi cells when compared
with the parental MDA-MB-231 cell line. Consistent with
increased uPA secretion in the supernatant fraction, we
also detected an increased level of plasmin activity in the
supernatant of the MDA-MB-231Hi cells relative to the
plasmin activity observed in the MDA-MB-231 cells, mea-
sured over a 3-hour period (Figure 2F).
HA and CD44 regulate uPA expression and activity in
basal-like breast cancer cells
We next sought to determine the association of HA and
CD44 to increased uPA expression and activity in BL-BCa
cells. Initially, MDA-MB-231 cells were stimulated with
HA to determine whether the native ligand of CD44
induced expression of uPA or that of its associated pro-
teins. Immunoblotting analysis confirmed that exogenous
HA increased the expression of uPA, uPAR, and PAI-1,
without affecting the expression of PAI-2 (Figure 3A);
marked increases in uPA and uPAR expression were
detected 9 hours after stimulation with HA. Furthermore,
qPCR analysis also revealed that exogenous HA increased
mRNA transcript levels for these genes in a second BL-
BCa cell line, Hs578T. Significant increases in uPA mRNA
transcript levels were prominent in Hs578T cells for 24
hours afterstimulation with HA, whereas mRNA transcript
levels for uPAR and PAI-1 were increased relative to those
detected for these genes in unstimulated cells (see
Additional file 2, Figure S2). Consistent with our observa-
tions of increased gene and protein expression in response
to exogenous HA, stimulation of MDA-MB-231 and
Hs578T cells with HA was shown to increase cell surface-
associated uPA activity in both of these BL-BCa cell lines
(Figure 3B).
The role of CD44 in regulating uPA and its associated
proteins was next investigated. A short-hairpin strategy
was used to downregulate CD44 mRNA and protein
expression in the MDA-MB-231Hi cell line (termed
MDA-MB-231 sh#1 cells). The effects of CD44 knock-
down were determined by comparison with MDA-MB-
231 NT cells, transfected with a nontargeting short hair-
pin and which retained CD44 expression (see Additional
file 3, Figures S3A and S3B). CD44 knockdown retarded
cell invasion through Matrigel (see Additional file 3, Fig-
ure S3C). Relative to a nontargeting short hairpin (NT),
loss of CD44 also coincided with a decrease in the tran-
script levels for uPA, uPAR, PAI-1, and PAI-2 (all P <
0.001) (see Additional file 3, Figure S3D) and a decreased
expression for each of these proteins (see Additional
file 3, Figure S3E).
To associate CD44 further in mediating HA-induced
increases in uPA gene expression and activity, we per-
formed another series of experiments using the MDA-
MB-231 sh#1 cells. In these experiments, the effect of
CD44 knockdown on the expression and activity of uPA
was determined in the absence and presence of an exo-
genous HA stimulus. Loss of CD44 not only coincided
with a decreased transcript level of uPA relative to that
in NT-transfected cells, as observed before, but also atte-
nuated the HA-promoted increases in uPA gene expres-
sion (Figure 3C). When further experiments were
conducted to measure uPA activity, MDA-MB-231 sh#1
cells had reduced cell-surface uPA activity under unsti-
mulated conditions, whereas the HA-induced increase in
uPA activity was severely truncated in the absence of
CD44 (Figure 3D).
Consistent with the observed decreases in uPA and
uPAR mRNA and protein expression, and the reduction in
uPA activity, the loss of CD44 was also shown to correlate
with a decrease in the plasmin activity associated with the
MDA-MB-231Hi cells (Figure 3E). The functional rele-
vance of this uPA-generated plasmin activity to HA-pro-
moted cell invasion was determined with a further
invasion assay in which plasmin activity was inhibited by
using aprotinin. HA failed to stimulate invasion in the pre-
sence of 1 μM aprotinin (Figure 3F).
uPA activity underpins HA-promoted invasion of basal-
like breast cancer cells
A further series of experiments was conducted to deter-
mine the importance of uPA in HA-promoted invasion.
Expression of uPA was inhibited by using RNAi.
Montgomery et al. Breast Cancer Research 2012, 14:R84
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Figure 2 Characterization of elevated expression or activity of the uPA signaling pathway in highly invasive breast cancer cells. (A) Bar
graph showing the comparable levels of mRNA transcript expression for uPA, uPAR, and its endogenous inhibitors PAI-1 and PAI-2 between MDA-MB-
231Hi and parental MDA-MB-231 cells. (B) Immunoblots showing the elevated uPA, uPAR, and PAI-1 expression and decreased PAI-2 expression in
MDA-MB-231Hi cells relative to MDA-MB-231 cells. The blots were reprobed with b-tubulin as a loading control. (C) Flow cytometry confirming
increased cell-surface uPAR expression in MDA-MB-231Hi cells (68.08% ± 3.770% shift relative to 40% ± 2.492% in MDA-MB-231 cells; P < 0.01; n = 3).
Next, activity assays were used to detect changes in uPA activity, measured within a “cell-associated” fraction (D) and within the supernatant (E) of the
cell culture. Activity of this serine protease was significantly higher in both the cell-associated fraction (2.64-fold increase; P < 0.01; n = 4) and the
supernatant (2.56-fold increase; P < 0.01; n = 4) of the MDA-MB-231Hi cells compared with the parental MDA-MB-231 cells. (F) An increased level of
plasmin activity was observed in the MDA-MB-231Hi cells relative to parental cells, conducted over a 3-hour period (P < 0.05; n = 4). Statistically
significant differences in all quantitative assays were determined by using a Student two-tailed t test (*P < 0.05; **P < 0.01; ***P < 0.001).
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Figure 3 CD44 signaling potentiates the expression and activity of uPA-signaling in breast cancer cells. (A) Immunoblot showing
enhanced uPA, uPAR, and PAI-1 protein expression on HA stimulation (100 μg/ml) of MDA-MB-231 cells. No change in PAI-2 protein expression
was found. All immunoblots shown were reprobed with GAPDH as a loading control. (B) Bar graph presenting time-dependent increases in cell
surface-associated uPA activity detected in MDA-MB-231 and Hs578 BL-BCa cells in response to exogenous HA stimulation (100 μg/ml). (C) Bar
graph comparing the mRNA transcript levels for uPA in MDA-MB-231 NT and MDA-MB-231 sh#1 cells, in the absence and presence of an
exogenous HA stimulus (100 μg/ml). (D) Bar graph comparing the cell surface-associated uPA activity in MDA-MB-231 NT and MDA-MB-231 sh#1
cells, in the absence and presence of an exogenous HA stimulus (100 μg/ml). (E) Bar graph comparing plasmin activity in MDA-MB-231 NT and
MDA-MB-231 sh#1 cells; the loss of CD44 was coupled with a decrease in plasmin activity in these BL-BCa cells (P < 0.05; n = 3). (E) Invasion
assays were conducted in HA-supplemented Matrigel in the presence or absence of aprotinin for a period of 36 hours. HA increased the cell-
invasion index of MDA-MB-231Hi cells from 0.3392 ± 0.1297 to 2.237 ± 0.1659 (P < 0.001). In the presence of 1 μM aprotinin, the cell-invasion
index was reduced to 0.4312 ± 0.3191 (P < 0.01 relative to HA alone; n = 3). Statistically significant differences in quantitative values were
determined by using a Student two-tailed t test (*P < 0.05; **P < 0.01; ***P < 0.001).
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Transfection with three increasing concentrations of
uPA-targeting oligonucleotides decreased protein
expression of uPA in the MDA-MB-231Hi cells (see Addi-
tional file 4, Figure S4A). Transfection with 200 nM uPA
RNAi significantly reduced transcript levels for uPA in the
MDA-MB-231Hi cells (see Additional file 4, Figure S4B)
and significantly decreased cell-surface associated and
secreted uPA activity in these cells (Figure 4A and 4B).
Furthermore, uPA knockdown significantly reduced the
invasiveness of MDA-MB-231Hi cells through Matrigel
(Figure 4C).
A pharmacologic approach used a small-molecule uPA
inhibitor to attenuate uPA activity. Administration of
this inhibitor to MDA-MB-231Hi cells reduced both cell
surface-associated uPA activity and uPA activity in the
supernatant in a concentration-dependent manner; at a
concentration of 30 μM, this inhibitor reduced superna-
tant activity to <5% of vehicle-treated control and
reduced cell surface-associated activity to 22 ± 6.1% of
vehicle-treated control (Figure 4D). In cell-invasion
assays, the addition of the uPA inhibitor (30 μM) abro-
gated the HA-stimulated invasion of the MDA-MB-
231Hi cells (Figure 4E).
CD44 signaling also increases expression of collagenolytic
proteases of the cysteine cathepsin and matrix-
metalloproteinase families in basal-like breast cancer cells
MDA-MB-231Hi cells were also observed to be more
invasive on a collagen I matrix relative to the parental
MDA-MB-231 cells (Figure 5A). Interestingly, MDA-
MB-231Hi cell invasion through collagen I was attenu-
ated by RNAi-mediated knockdown of CD44 (Figure 5B).
To determine whether this increased invasion through
collagen I was representative of a further difference in
protease activity, an in vitro fluorescence-based collage-
nolytic activity assay (EnzChek Gelatinase/Collagenase
assay; Molecular Probes) was used. Concentrated cell-
culture supernatants from MDA-MB-231 parental and
MDA-MB-231Hi cells were incubated with a DQ fluores-
cein-conjugated collagen I substrate, and fluorescence
was read at 30-minute intervals over an 8-hour period.
MDA-MB-231Hi cells demonstrated an increased ability
to degrade collagen I when compared with MDA-MB-
231 parental cells (Figure 5C).
uPA has no intrinsic ability to degrade collagen. There-
fore, we undertook experiments to identify additional dif-
ferentially expressed proteolytic species that can directly
promote collagen degradation and whose altered expres-
sion/activity may explain the marked difference in cell
invasion through collagen. Two of the most potent col-
lagen-degrading proteases are the membrane-tethered
matrix metalloproteinase MT1-MMP [26] and the
cysteine protease, cathepsin K [27]. qPCR analysis
demonstrated an increased mRNA transcript level for
cathepsin K (Figure 5D) and MT1-MMP in MDA-MB-
231Hi cells over parental cells (Figure 5E). Immunoblot-
ting also confirmed an elevated expression of MT1-MMP
and cathepsin K protein expression in the MDA-MB-
231Hi cells (Figure 5F), whereas an ELISA revealed an
increased secretion of cathepsin K in MDA-MB-231Hi
cells relative to parental cells (Figure 5G).
The role of HA in regulating the expression of these
proteases in invasive BL-BCa cells was studied in further
experiments. Addition of exogenous HA induced time-
dependent increases in MT1-MMP and cathepsin K
mRNA transcript levels (Figure 6A) and increased expres-
sion of both proteases (Figure 6B) in MDA-MB-231Hi
cells. HA-promoted increases in MT1-MMP gene expres-
sion was also observed in two further CD44-expressing
BL-BCa cell lines, MDA-MB-157 and Hs578T (Figure 6B),
whereas increases in cathepsin K transcript levels were
detected in MDA-MB-157 cells (see Additional file 5,
Figure S5). Furthermore, addition of HA also potentiated
cathepsin K secretion in MDA-MB-231HI cells (Figure
6C). Consistent with the HA-induced increases in cathe-
psin K and MT1-MMP expression, stimulation of the
MDA-MB-231Hi cells for 3 hours with HA increased the
rate of increase and the maximal collagenolytic activity
exerted by the MDA-MB-231HI cells by using the
EnzChek Gelatinase/Collagenase assay (Figure 6D).
Further experiments were conducted to confirm the
importance of CD44 in mediating the HA-induced
increases in the expression of these collagen-degrading
enzymes. Initially, RNAi-mediated depletion of CD44
expression in MDA-MB-231Hi cells was shown to result
in a reduced expression of MT1-MMP (Figure 7A) and
significantly decreased cathepsin K secretion (Figure
7B). In a further series of experiments, the knockdown
of CD44 in the MDA-MB-231 sh#1 cells was shown to
reduce mRNA transcript levels for cathepsin K (Figure
7C) and MT1-MMP (Figure 7D). Moreover, the pre-
sence of exogenous HA was unable to induce the
expression of either of these proteases in the MDA-MB-
231 sh#1 cells that had been rendered devoid of CD44
expression, in contrast to the positive change in protease
gene expression observed in the MDA-MB-231 NT cells
in response to HA (Figure 7C and 7D).
The functional importance of MT1-MMP and cathe-
psin K in underpinning invasion of these cells through a
collagen-I matrix was then investigated by using mole-
cular or pharmacologic approaches. RNAi was used to
suppress MT1-MMP expression in the MDA-MB-231Hi
cells (see Additional file 1, Figure S1B), whereas a com-
mercially available pharmacologic inhibitor was used to
antagonize cathepsin K activity in these cells. Inhibition
of MT1-MMP (Figure 7E) or cathepsin K (Figure 7F)
reduced the invasive capacity of these MDA-MB-231Hi
cells through collagen.
Montgomery et al. Breast Cancer Research 2012, 14:R84
http://breast-cancer-research.com/content/14/3/R84
Page 10 of 19
(A) 
(B) 
NT
 R
NA
i
NT
 R
NA
i
uP
A 
RN
Ai
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75 *
*
+ HA
C
el
l I
nv
as
io
n 
In
de
x
(C) 
VC 30 10 3 0.3
0
25
50
75
100 Cell Lysate
Cell Supernatant
+ uPA Inhibitor (μM)
uP
A 
ac
tiv
ity
(%
 V
eh
ic
le
 C
on
tr
ol
)
(D) 
(E) 
Co
nt
ro
l
Co
nt
ro
l
Ve
hic
le 
Co
nt
ro
l
uP
A 
Inh
ibi
to
r
0.0
0.5
1.0
1.5
2.0
2.5 *** *
*
+ HA
C
e
ll 
In
v
as
io
n
 In
d
e
x
NT
 R
NA
i
uP
A 
RN
Ai
0
25
50
75
100
**
**
u
P
A
 a
ct
iv
ity
 (%
 c
o
n
tr
o
l)
NT
 RN
Ai
uP
A R
NA
i
0
25
50
75
100
*
uP
A 
ac
tiv
ity
 (%
 co
nt
ro
l)
Figure 4 Downregulation of uPA activity attenuates the HA-promoted invasion of CD44-enriched invasive breast cancer cells. RNAi-
mediated reduction of uPA expression in MDA-MB-231Hi cells resulted in a decrease in (A) cell-surface uPA activity to 64.9% ± 10.8% of control
NT RNAi-transfected cells (P < 0.01; n = 3) and (B) secreted uPA to 33.1% ± 11.1% of control NT RNAi-transfected cells (P < 0.05; n = 3). (C) Bar
graph illustrating the HA-promoted invasion of MDA-MB-231 NT cells through Matrigel over a 12-hour period, in the absence and presence of a
uPA-targeting siRNA. HA (100 μg/ml) increased the cell-invasion index to 1.27 ± 0.36 (P < 0.05); however, this was attenuated by transfection
with the uPA RNAi SMARTPool (cell invasion index of 0.43 ± 0.1; P < 0.05 relative to HA alone; n = 4). (D) Bar graph presenting the effects of
administering an uPA inhibitor on uPA activity detected in MDA-MB-231Hi cells. (E) Bar graph illustrating the HA-promoted invasion of MDA-MB-
231Hi cells in the absence and presence of a uPA inhibitor. HA increased MDA-MB-231Hi cell invasion through Matrigel over a 36-hour period to
a mean cell index of 2.24 ± 0.2 (P < 0.001 relative to control cells). Treatment with the uPA inhibitor (30 μM) reduced the HA-promoted cell-
invasion index to 0.4 ± 0.09 (P < 0.05 relative to vehicle control; n = 3). Statistically significant differences were determined by using a Student
two-tailed t test (*P < 0.05; **P < 0.01; ***P < 0.001).
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Figure 5 Highly invasive breast cancer cells exhibit increased expression of collagen-degrading enzymes. (A) Bar graph illustrating the
comparable invasion of parental MDA-MB-231 and MDA-MB-231Hi cells through a collagen I matrix. (B) Bar graph illustrating the retardation of
MDA-MB-231Hi cell invasion through collagen I after transfection of the cells with a CD44 RNAi SMARTPool. (C) Bar graph presenting the
respective collagenolytic activity of MDA-MB-231 parental and MDA-MB-231Hi cells, determined by using the Enzchek Collagenase assay. Bar
graphs showing the results of quantitative real-time PCR analysis to determine mRNA transcript expression for (D) cathepsin K and (E) MT1-MMP
in parental MDA-MB-231 and MDA-MB-231Hi cells. MDA-MB-231Hi cells demonstrated a 3.98- and 1.98-fold increase in cathepsin K and MT1-
MMP, respectively, compared with their parental counterparts. (F) Immunoblot demonstrating elevated CD44, MT1-MMP, and cathepsin K protein
expression in MDA-MB-231Hi cells relative to MDA-MB-231 parental cells. Membranes were reprobed with b-tubulin as a loading control. (G)
Enzyme-linked immunosorbent assay (ELISA) showing elevated cathepsin K secretion in the MDA-MB-231Hi cells (6,170 ± 1,148 pmol/L/106 cells)
relative to MDA-MB-231 parental cells (2,164 ± 553.3 pmol/L/106 cells; P < 0.01; n = 6). Statistically significant differences were determined by
using a Student two-tailed t test (*P < 0.05; **P < 0.01; ***P < 0.001)
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Figure 6 Characterization of HA-induced potentiation of collagen-degrading enzymes and their role in underpinning CD44-mediated
invasion of breast cancer cells. (A) Bar graphs showing the induction of cathepsin K (left panel) and MT1-MMP (right panel) mRNA expression
after treatment with 100 μg/ml HA over a 12-hour period. All values were normalized against 18S mRNA expression, and fold-changes were
calculated by comparison of mRNA levels in the absence of HA stimulation. Data shown is the mean ± SEM fold-change relative to control
determined from three independent experiments. (B) A series of immunoblots confirming a time-dependent increase in the expression of
cathepsin K (top panel) and MT1-MMP (bottom panel) expression in response to HA-stimulation (100 μg/ml). Equal protein loading in
immunoblots was confirmed by reprobing the membranes for b-tubulin. (C) ELISA experiments conducted on MDA-MB-231Hi cells on 100 μg/
ml HA stimulation demonstrate a time-dependent increase in cathepsin K secretion from 6,437 ± 855.0 pmol/L/106 cells to 10,649 ± 860.5 pmol/
L/106 cells within 6 hours of HA treatment. Data points are the mean concentration of cathepsin K ± SEM relative to concentration of cathepsin
K in untreated MDA-MB-231Hi cells. (D) Stimulation of MDA-MB-231Hi cells with HA (100 μg/ml) for 3 hours potentiates the extracellular
collagenolytic activity of MDA-MB-231Hi cells by using the in vitro EnzChek Collagenase assay (P < 0.001; n = 5).
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Figure 7 CD44 regulates MT1-MMP and cathepsin K expression to underpin BL-BCa cell invasion. (A) Immunoblot showing reduced MT1-
MMP protein expression on transfection of MDA-MB-231Hi cells with a CD44-targeted RNAi SMARTPool relative to a nontargeting
oligonucleotide-transfected cell population. (B) Bar graph demonstrating the impact of CD44 knockdown on the secretion of cathepsin K by
MDA-MB-231Hi cells. Cathepsin K concentration was reduced from 23,310 ± 4,227 pmol/L/106 cells in NT cells to 10,380 ± 526.7 pmol/L/106 cells
in CD44-depleted cells (P < 0.05; n = 4). (C) Bar graph comparing the mRNA transcript levels for cathepsin K in MDA-MB-231 NT and MDA-MB-
231 sh#1 cells, in the absence and presence of an exogenous HA stimulus (100 μg/ml). (D) Bar graph comparing the mRNA transcript levels for
MT1-MMP in MDA-MB-231 NT and MDA-MB-231 sh#1 cells, in the absence and presence of an exogenous HA stimulus (100 μg/ml). (E) Bar
graph illustrating the effect of RNAi-mediated suppression of MT1-MMP in MDA-MB-231Hi cells on their invasion through collagen I. (F) Bar
graph showing the effect of administering a pharmacologic inhibitor of cathepsin K on the invasion of MDA-MB-231Hi cells through a collagen I
matrix. Statistically significant differences between data points in quantitative assays were determined by using a Student two-tailed t test. *P <
0.05; **P < 0.01; ***P < 0.001.
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HA induces transcriptional regulation of proteases
through a p38 mitogen-activated protein kinase pathway
HA previously was shown to regulate protease expres-
sion in chondrocytes and osteoclasts through induction
of p38 mitogen-activated protein kinase (MAPK)
[28,29]. Experiments were first conducted to determine
whether exogenous HA could induce this signaling
pathway in BL-BCa cells. Immunoblotting experiments
initially proved that the addition of HA induced a time-
dependent phosphorylation of p38 MAPK in MDA-MB-
231Hi cells (Figure 8a). The significance of p38 MAPK
in underpinning HA-induced transcription of the pro-
teases uPA, cathepsin K, and MT1-MMP in BL-BCa
cells was studied further. MDA-MB-231Hi cells were
stimulated for 9 hours with HA in the absence or pre-
sence of the p38 MAPK inhibitor SB203580 (2 μM).
The inhibition of p38 MAPK signaling was shown to
attenuate the HA-induced increase in the transcript
levels for uPA (Figure 8B), cathepsin K (Figure 8C), and
to abrogate the HA-induced expression of the MT1-
MMP gene to below basal levels (Figure 8D).
Discussion
Molecular stratification of gene-expression data has
defined a minimum of five distinct subtypes of breast
cancer [1]. Our analysis of breast tumor material deter-
mined that CD44 was inversely correlated with expres-
sion of the ER and PR, with no correlation to Her2, and
that enrichment of CD44 was associated with BL-BCa,
the subtype associated with the poorest clinical out-
come. Our tissue-based characterization is consistent
with other recent studies reporting the localization of
CD44 in BL-BCa [6]. The association of CD44 with the
most aggressive subtype of disease is consistent with the
well-established cellular functions of CD44 in promoting
cell invasion and cell adhesion in vitro, and the capacity
for CD44 to increase spontaneous metastasis of breast
cancer cells in vivo [7,8; McFarlane S, Coulter J, Waugh
DJJ, unpublished observations]. Bourguignon and collea-
gues [30-32] provided a detailed understanding of
CD44-promoted activation of Rho-GTPase family signal-
ing, underpinning the reorganization of the cell cytoske-
leton to facilitate the active migration of cells. The
Stamenkovic and Seiki laboratories also reported that
CD44 can complex with secreted and membrane-teth-
ered matrix metalloproteinases, localizing their proteoly-
tic activity to the invasive edge of tumor cells [11-14].
In this study, we now add a further dimension to our
understanding of CD44-promoted invasion of breast
cancer. In a series of experiments, conducted primarily
in MDA-MB-231 breast cancer cells, but supported by
additional observations in other well-established models
of ER-negative and BL-BCa, we show that HA and
CD44 can upregulate expression of key proteases that
underpin the invasion of BL-BCa cells through experi-
mental matrices. Importantly, our studies demonstrate
that CD44 affects the expression and activity of mem-
bers of the serine protease, cysteine cathepsin, and
matrix metalloproteinase family. Collectively, these
enzymes may contribute a spatial and temporal function
throughout the metastatic cascade, providing invasive
breast cancer cells with the essential complement of
proteolytic activity to traverse successfully the physical
barriers provided by the tissue matrix and basement
membranes in both the primary and secondary tissue
sites.
The serine protease uPA and its inhibitor PAI-1 are
bona fide markers of poor prognosis that predict distant
metastasis in breast cancer [15,16], whereas expression
of uPA is upregulated in tumor-initiating breast cancer
cells [33]. Highly invasive MDA-MB-231Hi cells were
shown to have elevated expression of uPA, uPAR, and
PAI-1 at transcript and protein levels, and had elevated
cell surface-associated and extracellular uPA activity.
We also detected increased plasmin activity in the
MDA-MB-231Hi cells, consistent with a more-efficient
uPA-mediated cleavage of its substrate plasminogen.
The addition of HA further increased the mRNA tran-
script levels for uPA, uPAR, and PAI-1 and increased
the levels of the corresponding proteins in a time-
dependent manner in these BL-BCa cells. Coincident
with the increased expression of uPA and uPAR, HA
increased the cell surface-associated activity of uPA in
these cells.
Conversely, the loss of CD44 in MDA-MB-231Hi cells
coincided with a decreased expression of uPA, uPAR,
PAI-1, and PAI-2, and attenuated the capacity of HA to
increase expression of uPA. Consequently, CD44-
depleted cells were associated with a decreased level of
plasmin activity.
The importance of these serine proteases to BL-BCa
cell invasion was investigated in vitro. Consistent with
the HA-induced promotion of initially uPA and subse-
quently plasmin activity, the serine protease inhibitor
aprotinin abrogated the HA-induced invasion of the
MDA-MB-231Hi cells through Matrigel. Similarly,
RNAi-mediated knockdown of uPA attenuated the inva-
sion of these BL-BCa cells, whereas an inhibition of
MDA-MB-231Hi cell invasion was also observed by
using a small-molecule inhibitor of uPA. In addition to
this role for uPA in promoting localized invasion of BL-
BCa cells, increased uPA activity was detected in highly
disseminating tumor cells and implicated in regulating
the intravasation of these disseminating cells [23-25].
Accordingly, CD44-positive BL-BCa cells may be more
efficient in completing intravasation, consistent with the
role of CD44 in promoting the spontaneous metastasis
of breast cancer in vivo [8] and the increased detection
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of CD44-enriched cells to disseminate to distant organs
[9,10]. Targeting of the enzymatic activity of uPA by
using small-molecule inhibitors may therefore be an
appropriate and effective adjuvant therapeutic strategy
to use in BL-BCa, or those breast cancers showing
strong expression of CD44, with the intent to reduce
distant metastasis and prolong survival in this poor-
prognosis group of patients. Importantly, the small-
molecule inhibitor used in this study was capable of
antagonizing both cell-surface and extracellular activities
of uPA, suggesting that its inhibitory potential is not
restricted by specific localization of the enzyme.
Collagen is a major constituent of the extracellular
matrix of primary and secondary tumor sites. MDA-MB-
231Hi cells showed increased capacity to degrade and
invade through collagen, a response also attenuated by
CD44 knockdown. As uPA has no capacity to degrade
collagen directly, a further analysis characterized
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Figure 8 HA-induced regulation of protease gene expression is attenuated by a p38 MAPK inhibitor. (A) Representative immunoblot
characterizing the time-dependent phosphorylation of p38 MAPK in MDA-MB-231Hi cells after stimulation with 100 μg/ml HA. Equal protein
loading in immunoblots was confirmed by reprobing the membranes for p38 MAPK and b-tubulin. Bar graphs illustrate the magnitude of HA-
induced increases in the mRNA transcript levels for (B) uPA, (C) cathepsin K, and (D) MT1-MMP, in the absence or presence of the p38 MAPK
inhibitor SB203580 (2 μM). The effect of the DMSO vehicle on the response was adjusted. Data shown are the mean ± SEM values calculated
from three independent experiments. Statistically significant differences between data points in quantitative assays were determined by using a
Student two-tailed t test. *P < 0.05; **P < 0.01.
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additional differential protease expression consistent with
this increased collagen-degrading activity in MDA-MB-
231Hi cells. Immunoblotting confirmed increased expres-
sion of two potent collagen-targeting proteases, MT1-
MMP and cathepsin K, in the more invasive cells.
Furthermore, HA increased (a) the transcript levels of
each of the MT1-MMP and cathepsin K genes, (b)
increased expression of the corresponding proteins, and
(c) promoted the extracellular secretion of cathepsin K.
As before, depletion of CD44 reduced the expression of
MT1-MMP and the secretion of cathepsin K from the
MDA-MB-231Hi cells, consistent with an overall reduc-
tion in the capacity of these cells to degrade collagen in
the absence of CD44. Furthermore, loss of CD44 attenu-
ated the HA-induced increases in protease expression,
underlying the importance of this receptor in mediating
the response. Loss of either MT1-MMP or cathepsin K
enzymatic activity was shown to reduce the HA-pro-
moted invasion of MDA-MB-231Hi cells through
collagen.
MT1-MMP promotes the cleavage of the ectodomain
of CD44 [13,14]. Our data suggest the existence of a
positive-feedback mechanism by which the engagement
of extracellular HA fragments with CD44 induces the
transcription of the protease responsible for promoting
the shedding of CD44 from the cell surface. Overall,
CD44 cleavage would attenuate cell attachment to HA
in the matrix and facilitate cell invasion. Moreover,
CD44, MT1-MMP, and cortactin have been shown to
localize to invadopodia [34], the membrane protrusions
that localize enzymes required for ECM degradation at
the leading edge of invasive cells. We suggest that CD44
may play an important hierarchic role in facilitating
invadopodia organization; for example, we showed that
CD44/HA-signaling increases the transcription and
expression of both MT1-MMP and EMS1/cortactin in
invasive BL-BCa cells [7]. Consistent with the past
observations of Bourguignon and colleagues [30], we
also confirmed that HA-induced CD44 signaling induces
a posttranslational activation of cortactin signaling in
these invasive breast cancer cells [30, McFarlane et al.,
unpublished data]. The capacity for CD44 to increase
MT1-MMP expression and promote its localization
within invadopodia would be consistent with the capa-
city of CD44 to induce breast cancer cell invasion.
MT1-MMP has multiple substrates within the extracel-
lular matrix, including collagen I, II, and III; fibronectin;
and each of laminin 1 and 5; in addition to having an
enzyme convertase function that leads to an activation
of the gelatinase MMP-2 and the collagenase MMP-13
[26,35]. Consequently, MT1-MMP activity is associated
with localized invasion but also contributes to the
degradation of basement membranes, a process essential
to successful intravasation and extravasation of tumor
cells. The capacity for CD44 to increase an enzyme that
can activate a downstream cascade of further MMP
activity would also be consistent with the role of this
receptor in enabling cells to complete metastasis to dif-
ferent tissue sites.
Cathepsin K is a member of the papain/cysteine pro-
tease superfamily [27]. Cathepsin K expression has pre-
viously been reported in primary human breast tumors
and their metastases, including breast cancer cells within
bone metastatic lesions [36]. Analysis of bone metastases
has reported CD44 expression on resident breast cancer
cells [9], whereas recent data from our laboratory con-
firm that loss of CD44 on systemically administered
MDA-MB-231 cells reduces secondary tumor formation
in athymic nude mice, including a reduction in osteoly-
tic metastases [McFarlane et al., unpublished data].
Furthermore, the inhibition of hyaluronan synthesis in
MDA-MB-231 cells has been reported to reduce subse-
quent bone metastasis in vivo [37]. Thus CD44-pro-
moted increases in cathepsin K expression and secretion
may assist the initial invasion and colonization of BrCa
cells within collagen-enriched secondary sites, including
the bone.
In summary, we define the importance of CD44 in
underpinning the invasion of BL-BCa cells, and illustrate
the importance of HA and CD44 in upregulating a
diverse spectrum of protease expression and activity that
can function in a spatial or temporal manner to enable
invasive cells to remodel their localized environment or
perform specialist functions, including the successful
completion of intravasation and extravasation. The capa-
city of CD44 to induce protease activity is consistent
with the aggressive clinical characteristics of BL-BCa
and the increased propensity to invade locally through
primary breast tissue and to colonize collagen-enriched
organs, including the liver, lungs, brain, and skin. Thus
the detection of high CD44 expression in tumor biopsy
tissue may be a suitable biomarker to identify patients
who may benefit from the provision of MT1-MMP- or
uPA-targeting therapeutics to reduce the risk of intrava-
sation and distant metastasis. Moreover, as CD44-
enriched “stem cell-like” breast cancer cells have been
shown to disseminate early in the course of disease
[9,10], inhibitors of these key protease activities may be
a relevant adjuvant approach to counteract the success-
ful invasion and colonization of secondary tissues by
these invasive breast cancer cells.
Additional material
Additional file 1: Validation of the siRNA-mediated knockdown of
CD44 and MT1-MMP. (A) Representative immunoblot showing the
reduction in CD44 expression in MDA-MB-231Hi cells, by using increasing
concentrations of a CD44-targeting RNAi-oligonucleotide or a
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nontargeting (NT) RNA-oligonucleotide. (B) Representative immunoblot
showing MT1-MMP protein levels detected in MDA-MB-231Hi cells
transfected with RNAi-oligonucleotides targeting these proteins. Cells
were also treated with an NT RNAi oligonucleotide as a control. Equal
protein loading in immunoblots was confirmed by reprobing the
membranes for b-tubulin.
Additional file 2: Characterization of HA-induced gene transcription
in Hs578T cells. Bar graph illustrating the relative change in mRNA
transcript levels in uPA, uPAR, and PAI-1 in the Hs578T BL-BCa cell line, in
response to stimulation with 100 μg/ml HA. Data shown are the mean ±
SEM value calculated from three independent experiments. Statistically
significant differences between data points in quantitative assays were
determined by using a Student two-tailed t test. *P < 0.05; **P < 0.01;
***P < 0.001.
Additional file 3: Characterization of a CD44-depleted clone of the
highly invasive breast cancer cells and the relation to uPA signaling
components. (A) Bar graph showing decreased CD44 mRNA transcript
levels present in the MDA-MB-231 sh#1 cells relative to MDA-MB-231 NT
cells (P < 0.001; n = 4). (B) Representative immunoblot showing
knockdown of CD44s expression in the MDA-MB-231 sh#1 cells
compared with the MDA-MB-231 NT cell line. The blots were reprobed
with b-tubulin as a loading control. (C) Bar graph illustrating the
attenuated invasive potential of MDA-MB-231 sh#1 cells through Matrigel
relative to the MDA-MB-231 NT cells (P < 0.05; n = 3). (D) Bar graphs
showing decreased mRNA transcript levels of uPA, uPAR, PAI-1, and PAI-2
in the MDA-MB-231 sh#1 cells relative to MDA-MB-231 NT cells (P <
0.001 for all genes; data shown are from a minimum of four
independent experiments). (E) Immunoblots demonstrating the
decreased expression of uPA, uPAR, PAI-1, and PAI-2 protein in MDA-MB-
231 cells in which CD44 expression had been decreased by using a
short-hairpin strategy (MDA-MB-231 sh#1) relative to nontargeting
control cells (MDA-MB-231 NT). All data points shown are mean ± SEM,
and statistically significant points were determined by using a Student
two-tailed t test. *P < 0.05; ***P < 0.001.
Additional file 4: Characterization of the siRNA-mediated
knockdown of uPA in highly invasive breast cancer cells. (A) uPA
RNAi validation in the MDA-MB-231Hi cell line. Immunoblot shows a
substantial reduction in uPA protein levels present in MDA-MB-231Hi
cells transfected with 200, 150, and 75 nM concentrations of uPA RNAi.
Cells were also treated with an NT RNAi oligonucleotide at each
concentration as a control. Blots were reprobed with GAPDH as a
loading control. (B) Bar graph showing a significant reduction in uPA
mRNA levels present in MDA-MB-231Hi cells after transfection with 200
nM uPA RNAi relative to NT RNAi-treated cells (P < 0.001; n = 4). Blots
were reprobed with b-tubulin as a loading control. Statistically significant
points were determined by using a Student two-tailed t test. ***P <
0.001.
Additional file 5: CD44 signaling potentiates cathepsin K expression
in the MDA-MB-157 BL-BCa cell line. q-PCR was conducted on RNA
isolates extracted from MDA-MB-157 cells over a 12-hour time course
after stimulation with HA (100 μg/ml). Data shown represent HA-
mediated increases in the mRNA expression of cathepsin K. Data points
are the mean ± SEM fold-change relative to control, determined from
three independent experiments.
Abbreviations
BL-BCa: basal-like breast cancer; HA: hyaluronan; MMP: matrix
metalloproteinase; PAI-1/2: plasminogen activator inhibitor-1/2; RNAi: small
interfering RNA; shRNA: short-hairpin RNA; TMA: tissue microarray; uPA:
urokinase plasminogen activator; uPAR: urokinase plasminogen activator
receptor.
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